Merck And The 'Strange Business' Of Antibiotics
Executive Summary
Antibacterials have been part of Merck's mission for decades, despite the market challenges, and it's expecting two new approvals this year. Infectious disease VP Joan Butterton talks about tackling those challenges and incentives that may help the industry address antimicrobial resistance.
You may also be interested in...
Voluntary Limits On Antibacterial Discharges Increase As Fear Of Resistance Grows
Pharmaceutical companies are ratcheting up voluntary efforts to control discharges of antimicrobials from their plants and those of their active pharmaceutical ingredient suppliers so they won’t contribute to antimicrobial resistance. But will it be enough to fend off regulation in countries like India?
Keeping Track: Recarbrio Approval Highlights Two-Week Roundup
The latest drug development news and highlights for our US FDA Performance Tracker.
Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path
Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.